- Home
- PHAT vs CCSI Comparison
PHAT vs CCSI Comparison
Compare PHAT & CCSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- CCSI
- Stock Information
- Founded
- PHAT 2018
- CCSI 2021
- Country
- PHAT United States
- CCSI United States
- Employees
- PHAT N/A
- CCSI N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- CCSI Retail: Computer Software & Peripheral Equipment
- Sector
- PHAT Health Care
- CCSI Technology
- Exchange
- PHAT Nasdaq
- CCSI Nasdaq
- Market Cap
- PHAT 539.5M
- CCSI 476.8M
- IPO Year
- PHAT 2019
- CCSI N/A
- Fundamental
- Price
- PHAT $8.32
- CCSI $24.43
- Analyst Decision
- PHAT Strong Buy
- CCSI Hold
- Analyst Count
- PHAT 4
- CCSI 5
- Target Price
- PHAT $23.00
- CCSI $26.00
- AVG Volume (30 Days)
- PHAT 992.3K
- CCSI 95.2K
- Earning Date
- PHAT 11-07-2024
- CCSI 11-07-2024
- Dividend Yield
- PHAT N/A
- CCSI N/A
- EPS Growth
- PHAT N/A
- CCSI 16.33
- EPS
- PHAT N/A
- CCSI 4.56
- Revenue
- PHAT $26,270,000.00
- CCSI $351,153,000.00
- Revenue This Year
- PHAT $7,622.43
- CCSI N/A
- Revenue Next Year
- PHAT $236.87
- CCSI N/A
- P/E Ratio
- PHAT N/A
- CCSI $5.31
- Revenue Growth
- PHAT N/A
- CCSI N/A
- 52 Week Low
- PHAT $6.07
- CCSI $11.62
- 52 Week High
- PHAT $19.71
- CCSI $27.90
- Technical
- Relative Strength Index (RSI)
- PHAT 36.67
- CCSI 48.35
- Support Level
- PHAT $7.81
- CCSI $23.83
- Resistance Level
- PHAT $8.56
- CCSI $24.71
- Average True Range (ATR)
- PHAT 0.59
- CCSI 0.93
- MACD
- PHAT 0.22
- CCSI -0.18
- Stochastic Oscillator
- PHAT 38.28
- CCSI 19.02
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.